West Pharmaceutical Services (NYSE:WST - Get Free Report) had its price objective lifted by stock analysts at KeyCorp from $325.00 to $350.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the medical instruments supplier's stock. KeyCorp's price objective points to a potential upside of 13.82% from the company's current price.
Several other analysts have also recently issued reports on WST. Rothschild & Co Redburn assumed coverage on West Pharmaceutical Services in a research report on Monday, September 15th. They set a "buy" rating and a $311.00 target price on the stock. UBS Group raised their price objective on West Pharmaceutical Services from $285.00 to $320.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Evercore ISI boosted their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an "outperform" rating in a research note on Thursday. Barclays boosted their target price on West Pharmaceutical Services from $260.00 to $275.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 2nd. Finally, Redburn Partners set a $311.00 target price on West Pharmaceutical Services in a research note on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, West Pharmaceutical Services currently has an average rating of "Moderate Buy" and an average price target of $329.11.
Read Our Latest Report on West Pharmaceutical Services
West Pharmaceutical Services Stock Up 11.0%
Shares of NYSE WST opened at $307.51 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.08 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $22.11 billion, a PE ratio of 46.03, a price-to-earnings-growth ratio of 4.86 and a beta of 1.07. The stock's fifty day simple moving average is $258.26 and its two-hundred day simple moving average is $233.39. West Pharmaceutical Services has a 12-month low of $187.43 and a 12-month high of $352.33.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.29. The business had revenue of $804.60 million for the quarter, compared to analysts' expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%.The business's revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, analysts expect that West Pharmaceutical Services will post 6.62 EPS for the current fiscal year.
Institutional Trading of West Pharmaceutical Services
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT acquired a new stake in West Pharmaceutical Services during the 1st quarter worth about $25,000. CYBER HORNET ETFs LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at about $25,000. Quarry LP purchased a new position in shares of West Pharmaceutical Services during the 1st quarter valued at about $27,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of West Pharmaceutical Services by 193.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 95 shares during the last quarter. Finally, SJS Investment Consulting Inc. raised its stake in shares of West Pharmaceutical Services by 1,842.9% during the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 129 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company's stock.
About West Pharmaceutical Services
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
